SEATTLE, May 8, 2015 /PRNewswire/ -- Adaptive Biotechnologies, the leader in next generation sequencing (NGS) to profile T- and B-cell receptors of the adaptive immune system, and its collaborators will present data demonstrating how profiling a patient's T-cell
repertoire may lead to diagnostic and therapeutic discovery in immune-mediated diseases at the American Association of Immunologists (AAI) Annual Meeting in New Orleans from May 8-11, 2015.
The aim of this research project is to develop new glycan-based nanomedicines targeted to DC to induce powerful T-cell
The study presented at the International Liver Congress 2014 detected and expanded MHC-multimer-positive CD8+ T-cells
specific for targeted GPC3 epitopes and grew T-cell
clones, from which the most specific and active T-cell
receptor was isolated.
lymphoma comprises 10% to 25% of all primary lymphomas of the small intestine, and it is the most common malignancy associated with celiac disease.
Scientists at the University were able to solve the molecular structure of the enhanced T-cell
receptor, bound to a fragment from a melanoma cell.
1) Extranodal natural killer T-cell
) lymphoma, which is extremely rare and highly aggressive, mainly affects the nasopharyngeal area and the nasal cavity; when it occurs in other remote sites, the prognosis is usually unfavorable.
receptor gene rearrangement studies were positive in 25 out of 26 evaluated cases (96%).
JPT offers four delivery options for T-cell
assays: 1) Fast Track for proteome-wide T-cell
epitope discovery programs 2) Research Track for T-cell
epitope mapping studies 3) Discovery Track for immune monitoring applications and 4) Trial Track for vaccination trials.
New treatments, now under development, aim at blocking the functions of the T-cell
receptor and the CD28 molecule in order to dampen attacks on the nervous system.
This small molecule drug is being developed for treatment of T-cell
malignancies, and has been designated an "Orphan Drug" for broader indications, including cutaneous T-cell
lymphoma (CTCL), chronic lymphocytic leukemia (CLL) and acute lymphoblastic leukemia (ALL), by the FDA.
National Institute of Allergy and Infectious Diseases (NIAID) reported that an experimental vaccine clearly improved the survival of monkeys after infection by SIV (simian immunodeficiency virus), a virus similar to HIV--even though it did not prevent infection, and did not much improve viral load or total T-cell
Data from a clinical trial presented at the American Society of Hematology 46th Annual Meeting and Exposition (ASH) demonstrated MabCampath (alemtuzumab) was effective in the first-line treatment of peripheral T-cell
non Hodgkin's Lymphoma (NHL).